Delving into the Latest Updates on Malesci Istituto Farmacobiologico SpA with Synapse

Overview

7-[(2,2-Dimethyl)propyl]-1-methyl xanthine (CAS 155006-67-0, MX2/120) is a new potent antibronchospastic agent with negligible side effects. The synthesis involves the alkylation of 3-benzyl-1-methyl xanthine with neopentyl bromide followed by removal of the benzyl protecting group. Main physico-chemical properties were determined using NMR, MS, IR, UV spectra and X-ray crystal structure. A quantitative determination of substances related to MX2/120 and of residual solvents by means of HPLC and GC, respectively, is described. MX2/120 is safely stored at room temperature for a long time.

01 May 1995·Arzneimittel-Forschung

Pharmacodynamic profile of the new potent antibronchospastic agent 7-[(2,2-dimethyl)propyl]-1-methyl xanthine.

Article

Author: Castellucci, A ; Toja, E ; Ballati, L ; Tramontana, M ; Boni, P ; Perretti, F ; Evangelista, S

The pharmacodynamic profile of a new xanthine derivative, 7-[(2,2-dimethyl)propyl]-1-methyl xanthine (CAS 155006-67-0, MX2/120), was investigated in comparison with theophylline. The compound reduces in vitro the bronchospastic tone induced by carbachol or histamine in guinea-pig bronchi, with a potency 11 and 5 fold greater than theophylline, respectively. MX2/120 is significantly more active and long-lasting than theophylline in in vivo experiments toward spasmogens such as acetylcholine (ED50 over 5 h = 15 mumol/kg p.o. vs 230 mumol/kg p.o.) or histamine (ED50 over 5 h = 122 mumol/kg p.o. vs 500 mumol/kg p.o.) while being almost equiactive to theophylline toward antigen and capsaicin induced cough strokes. MX2/120, if administered by i.p. route reduces hyperresponsiveness to histamine induced by PAF and extravasation of protein into bronchoalveolar lavage fluid induced by capsaicin. These anti-inflammatory effects of MX2/120 are of similar extent when compared to theophylline. Unlike theophylline, MX2/120 up to 275 mumol/kg p.o. possesses little or no CNS excitatory effects in mice in terms of reduction of sleeping time induced by chlordiazepoxide, increase in mortality and convulsions induced by pentetrazol and increase in locomotor activity. This reduced neuroexcitatory action is probably related to its lack of affinity to adenosine receptors that could also explain the absence of effect on basal gastric secretion. Chronotropic effects of MX2/120 in conscious rats are similar to those of theophylline while the effects of both drugs on blood pressure are of minor extent. The overall pharmacodynamic properties of MX2/120 are superior to those of theophylline in relation to its antibronchospastic activity and lack of excitatory effects on CNS.

01 May 1995·Farmaco (Societa chimica italiana : 1989)

A new class of antibronchospastic agents: 7-(2,2-dimethyl)propyl substituted xanthines.

Article

Author: Ballati, L ; Di Marco, G ; Castellucci, A ; Borgianni, M ; Bonacchi, G ; Agostini, O ; Evangelista, S ; Boni, P ; Toja, E

A series of 7-(2,2-dimethyl)propyl substituted xanthines were synthesized and tested for their antibronchospastic activity in comparison with theophylline. In vitro, the inhibition of carbachol-induced increase in bronchial tone was determined. In vivo, the inhibition of antigen-induced bronchoconstriction in guinea pigs was determined 1, 3 and 5 h after oral administration. Central side effects were evaluated. In vitro, the majority of compounds were more effective than theophylline. In vivo, three compounds 2, 14 and 15 showed an effect comparable to theophylline but longer lasting. A mild sedative effect was generally observed. Compound 2, 7-(2,2-dimethyl)propyl-1-methyl xanthine, coded MX2/120, was selected for a deeper evaluation.

100 Deals associated with Malesci Istituto Farmacobiologico SpA

Login to view more data

100 Translational Medicine associated with Malesci Istituto Farmacobiologico SpA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IP-66 ( ADRA1 )	Hypertension More	Discontinued
MX-2120 ( Phosphoric diester hydrolases )	Asthma More	Discontinued
Isbufylline ( cGMP-PDE )	Asthma More	Discontinued